Rx Peps Direct has been named Best Online Peptide Therapy Provider 2026 by American Recognition Awards, recognizing its flat-fee medical review model and direct-to-pharmacy wholesale pricing.
Rx Peps Direct has been named the winner of Best Online Peptide Therapy Provider 2026 by American Recognition Awards. The recognition comes as the Fort Collins, Colorado-based telehealth practice is in its first year of operation, having taken its first patients in May 2026 and now serving 28 states plus Washington, DC.
The award highlights a model built around a simple premise: patients should pay for real medical oversight, then pay the pharmacy's wholesale price directly. Rx Peps Direct charges a flat $39 medical review per order, covering up to three peptides, and makes nothing on the medication itself. Every prescription goes to a licensed U.S. 503A compounding pharmacy, which fills it, ships it FedEx overnight pre-reconstituted and ready to inject, and bills the patient directly at wholesale, the same rate a clinic pays before adding its markup.
That structure has attracted a patient base that extends well beyond weight loss. More than half of Rx Peps Direct patients come for recovery and repair peptides, and about six in ten have never ordered a weight-loss product. The practice offers 65+ peptide and wellness formulations for recovery, weight loss, longevity, cognitive health, and sexual health, available by prescription after a two-minute health intake and review by a licensed provider.
Safety is built into the process. Peptides that conflict with a patient's history are removed automatically before a provider reviews the order, and the practice publishes sterility and endotoxin lab reports for every batch the pharmacy has shared. To date, more than 200 batch lab reports have been published. Rx Peps Direct prescribes only non-controlled peptides and requires no membership. Compounded medications are not FDA-approved.
Since launch, the practice has processed 3,051 approved orders for 1,759 patients as of October 19, 2026, and now operates with 55 physician-reviewed dosing protocols written by Medical Director Dr. Jonathan Snipes, MD. The company was founded in 2026 by Marcus Hansen, who serves as CEO, with Dr. Snipes as co-founder and Medical Director.
Hansen, a peptide user himself, started the company after growing uneasy with the gray market for research peptides. "As a peptide user myself, the research peptides made me nervous. They came with zero medical oversight," he said. "After researching forums and talking to people directly, I realized I wasn't the only one who felt that way. The question was how to keep it affordable, and the answer was simple: pay for real medical oversight, then pay the pharmacy's wholesale price directly from the pharmacy itself."
The American Recognition Awards honor organizations that demonstrate excellence in their field. For Rx Peps Direct, the 2026 designation reflects a first year of steady growth and a commitment to transparent pricing and medical oversight in the peptide therapy space.